The goal of this clinical trial is to learn if a combination of varenicline and accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS to varenicline + sham (inactive) aTMS to see the effect of aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?
Participants will be asked to:
* Complete 2 brain MRI scans * Take varenicline every day for 12 weeks * Quit using nicotine products at the end of the second week of varenicline * Complete 5 consecutive days (Monday-Friday, uninterrupted) of TMS treatments * Complete 12 brief, weekly follow-up visits * Complete a brief daily survey each day that they take the study drug
Age ≥ 18 and ≤65;
The ability to give written, informed consent;
Fluency in English;
Reported interest in quitting nicotine vaping or smoking within the next month;
Pregnancy or breastfeeding;
Use of smoking cessation pharmacotherapy in the past month;
Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;
Prior adverse drug reaction to varenicline;
Massachusetts General Hospital
Lead sponsor
Brigham and Women's Hospital
Collaborator